VasGene Therapeutics, Inc. – Product Pipeline Review – 2012

VasGene Therapeutics, Inc. – Product Pipeline Review – 2012


November 28, 2012
21 Pages - SKU: GMD4922708
License type:
Online Download      US $1,500.00
Site License      US $3,000.00
Global Site License      US $4,500.00


VasGene Therapeutics, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “VasGene Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on the VasGene Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, VasGene Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from VasGene Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • VasGene Therapeutics, Inc. - Brief VasGene Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of VasGene Therapeutics, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of VasGene Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the VasGene Therapeutics, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate VasGene Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of VasGene Therapeutics, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the VasGene Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with VasGene Therapeutics, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of VasGene Therapeutics, Inc. and identify potential opportunities in those areas.



More V - Companies reports by Global Markets Direct

Vectura Group plc - Product Pipeline Review - 2014 by Global Markets Direct
Vectura Group plc - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Vectura Group plc - Product Pipeline Review - 2014’, provides an overview of the ...
Vivia Biotech, S.L. - Product Pipeline Review - 2013 by Global Markets Direct
Vivia Biotech, S.L. - Product Pipeline Review - 2013SummaryGlobal Market Direct’s pharmaceuticals report, “Vivia Biotech, S.L. - Product Pipeline Review - 2013” provides data on ...
Vitae Pharmaceuticals, Inc. - Product Pipeline Review - 2013 by Global Markets Direct
Vitae Pharmaceuticals, Inc. - Product Pipeline Review - 2013SummaryGlobal Market Direct’s pharmaceuticals report, “Vitae Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on ...
VistaGen Therapeutics, Inc. - Product Pipeline Review - 2013 by Global Markets Direct
VistaGen Therapeutics, Inc. - Product Pipeline Review - 2013SummaryGlobal Market Direct’s pharmaceuticals report, “VistaGen Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on ...
See all reports like this >>

 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!